🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

A Global Health Concern

The sexually transmitted infection are increasing worldwide, with figures suggesting in excess of 82 million new cases each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, escalating drug resistance and the extremely scarce treatment choices currently available.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has listed it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Outcomes and Global Access

Based on findings released by a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which uses a dual-drug approach. The study included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of developing nations.

Clinicians on the front lines have voiced optimism. Access to a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is deemed vital to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.